Correction to: Neuropsychopharmacology 10.1038/s41386-021-01004-7, published online 05 April 2021
The original version of this article unfortunately mischaracterized the pharmacology of ibogaine.
The corrected text is as follows:
The recent report in Nature from Cameron et al. (2021)4 offers tantalizing evidence that non-hallucinogenic psychedelic compounds may possess beneficial actions. The authors started with ibogaine, a powerful hallucinogenic plant alkaloid with low affinity for serotonin and dopamine transporters, as well as kappa opioid receptors4,5. They then synthesized a novel analog of ibogaine called tabernanthalog (TBG). TBG is shown to have unique pharmacological properties and to lack many of the negative side effects of ibogaine.